Current Studies

SURMOUNT-2

Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight:

Checking Weight
Enrolling

Type of Study:
A Randomized, Double- Blind, Placebo-Controlled Trial for weight maintenance or weight loss for participants who have obesity or are overweight with weight-related diseases.

Study Length:
Approximately 79 weeks (22 visits)

Target Age/Sex:
over 18 years, Male and Female

Benefits:
Participants will receive at no cost: study product, study materials and study-specific procedures

Link: ClinicalTrials.gov

Staus: Enrolling

Description:

This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight.

TRAVERSE

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events and Efficacy Measures in Hypogonadal Men

Type of Study:
Blinded placebo controlled of topical Testosterone replacement therapy

Study Length:
5 years

Target Age/Sex:
45 - 80, Male

Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.

Link: ClinicalTrials.gov

Staus: Enrolling

Description:

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events and Efficacy Measures in Hypogonadal Men

Man in Nature
Enrolling

ANJ900D3501

A randomized, multicenter, double-blind, parallel-group, placebo- and comparator-controlled study to compare the glycemic effects, safety, and tolerability of Metformin hydrochloride delayed-release tablets in patients with type 2 Diabetes Mellitus with varying renal function from normal up to CKD3b

Prescription Drugs
Enrolling

Indication:

Type 2 diabetes mellitus (T2DM) with estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2

Study Length:
Approximately 52 weeks (22 visits)

Target Age/Sex:
over 18 years, Male and Female

Benefits:
Participants will receive at no cost: study product, study materials and study-specific procedures

Link: ClinicalTrials.gov

Staus: Enrolling

Description:

This is a Phase 3, 52-week, multicenter study with a 28-week, randomized, double-blind, parallel-group, placebo- and comparator-controlled treatment period (Double-Blind Treatment Period) and 24-week, open-label extension period (Open-Label Extension Period) that will be conducted in approximately 675 patients with T2DM with varying renal function from normal up to CKD3B who are treated with metformin preparation at the time of study screening.

CSL346_2001

VEGF-B Blockade with the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease

Type of Study:A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade with the Monoclonal Antibody CSL346 in Subjects with Diabetic Kidney Disease

Study Length:
7 months

Target Age/Sex:

over 18 years, Male and Female

Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.

Link: ClinicalTrials.gov

Staus: Enrolling

Description:

This is a prospective, multicenter, randomized, double-blind, placebo-controlled, proof of concept study to investigate the efficacy, safety, tolerability, and pharmacokinetics (PK) of repeat doses of CSL346 in subjects with DKD and albuminuria receiving standard of care treatment.

Drug and Syringe
Enrolling